Globe Newswire (Wed, 3-Jun 10:13 PM ET)
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Globe Newswire (Wed, 3-Jun 7:19 AM ET)
Globe Newswire (Tue, 2-Jun 8:25 AM ET)
Globe Newswire (Mon, 1-Jun 8:30 AM ET)
Celcuity To Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 28-May 8:30 AM ET)
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 14-May 4:01 PM ET)
Globe Newswire (Thu, 14-May 7:30 AM ET)
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Globe Newswire (Thu, 7-May 8:00 AM ET)
Market Chameleon (Mon, 4-May 6:31 AM ET)
Celcuity’s VIKTORIA-1 Trial Marks Major Advance in PIK3CA Mutant Breast Cancer Treatment
Market Chameleon (Mon, 4-May 3:06 AM ET)
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Celcuity trades on the NASDAQ stock market under the symbol CELC.
As of June 15, 2026, CELC stock price declined to $88.24 with 1,018,684 million shares trading.
CELC has a beta of 0.35, meaning it tends to be less sensitive to market movements. CELC has a correlation of 0.00 to the broad based SPY ETF.
CELC has a market cap of $4.30 billion. This is considered a Mid Cap stock.
In the last 3 years, CELC traded as high as $151.02 and as low as $7.58.
The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
CELC has outperformed the market in the last year with a return of +602.5%, while the SPY ETF gained +26.2%. However, in the most recent history, CELC shares have underperformed the stock market with its stock returning -20.3% in the last 3 month period and -33.6% for the last 2 week period, while SPY has returned +13.6% and -0.2%, respectively.
CELC support price is $84.29 and resistance is $92.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.